Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Plaintiff in first Zantac lawsuit set for trial drops case

Sports & General Aug 17, 2022 02:56PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: A bottle of Zantac heartburn drug is seen in this picture illustration taken October 1, 2019. REUTERS/Brendan McDermid/Illustration 2/2
 
PFE
-0.81%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MS
-2.26%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
SNY
-0.50%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GSK
-0.22%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BAYRY
-1.19%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Brendan Pierson and Natalie Grover

(Reuters) - The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.

Tuesday's news came days after shares of GlaxoSmithKline (NYSE:GSK) Plc, Sanofi (NASDAQ:SNY) SA, Pfizer Inc (NYSE:PFE) and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer.

The first trial in one of those lawsuits had been scheduled to begin on Monday in Illinois state court. The plaintiff, Joseph Bayer (OTC:BAYRY), alleged he developed esophageal cancer from taking over-the-counter Zantac.

Alexandra Walsh, an attorney for Bayer, said her client could not proceed for "personal health reasons" but had the right to refile his case within a year.

Zantac, originally marketed by a forerunner of GSK, has been sold by several companies at different times, including Pfizer, Boehringer Ingelheim and Sanofi as well as a plethora of generic drugmakers.

Haleon, spun out as an independent company last month, comprises consumer health assets once owned by GSK and Pfizer.

GSK and Boehringer Ingelheim said they had not paid anything in exchange for the voluntary dismissal of the Bayer case.

This result reflects what Pfizer has always stated: this litigation is without merit, a company spokesperson said.

Haleon and Sanofi were not named as defendants in the case.

Separately on Tuesday, Bloomberg reported a handful of generic companies including Teva, Perrigo, Sun Pharmaceutical Industries and Dr. Reddy’s Laboratories agreed to settle with Bayer for a total of more than $500,000 before the case was set to go to trial, citing people familiar with the deal.

A Perrigo spokesperson told Reuters the company had been dismissed from the Bayer case, per public records. "We are not commenting on the article, which is riddled with inaccuracies," the person said.

Teva Pharmaceuticals said it had been dismissed from a vast majority of claims in the multi-district litigation, but settled in a case that was not part of the litigation at a "nominal value" far less than what it would have cost in trial.

Sun Pharma and Dr Reddy's did not immediately respond to requests for comment.

Concerns around Zantac - known chemically as ranitidine - containing potential cancer-causing impurities started to emerge in 2018, well after generic versions of the medicine had been launched.

FINANCIAL IMPACT

More than 2,000 lawsuits are consolidated in federal court in West Palm Beach, Florida, where a hearing on what expert evidence will be allowed in future trials is scheduled for Sept. 20.

The first federal court trials are expected some time next year, though a highly favorable ruling for the companies on evidence could effectively end the litigation before then.

There is considerable uncertainty surrounding the potential total financial impact of the Zantac litigation, Morgan Stanley (NYSE:MS) analysts wrote in a note on Monday.

"There is also a scenario of zero liability if the defendants win the early cases," they wrote.

At the heart of the claims is an impurity, called N-nitrosodimethylamine (NDMA), which is considered a probable carcinogen.

U.S. regulators in 2020 determined the presence of the impurity in some ranitidine products increases over time and when stored at higher than room temperatures - and could therefore result in exposure to unacceptable levels of NDMA.

Meanwhile, Zantac makers strongly contest the once widely used drug's causal link to cancer, suggesting that NDMA levels in the medicine are close to what was found in common foods like grilled and smoked meats.

Plaintiff in first Zantac lawsuit set for trial drops case
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email